Cargando…

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial

OBJECTIVES: Risk factors for cardiovascular events are well established in general populations and those with diabetes but have been sparsely studied in impaired glucose tolerance (IGT). We sought to identify predictors of (1) a composite cardiovascular outcome (cardiovascular death, non-fatal myoca...

Descripción completa

Detalles Bibliográficos
Autores principales: Preiss, David, Thomas, Laine E, Sun, Jie-Lena, Haffner, Steven M, Holman, Rury R, Standl, Eberhard, Leiter, Lawrence A, Mazzone, Theodore, Rutten, Guy E, Tognoni, Gianni, Martinez, Felipe A, Chiang, Fu-Tien, Califf, Robert M, McMurray, John J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533049/
https://www.ncbi.nlm.nih.gov/pubmed/23204139
http://dx.doi.org/10.1136/bmjopen-2012-001925
_version_ 1782254382870429696
author Preiss, David
Thomas, Laine E
Sun, Jie-Lena
Haffner, Steven M
Holman, Rury R
Standl, Eberhard
Leiter, Lawrence A
Mazzone, Theodore
Rutten, Guy E
Tognoni, Gianni
Martinez, Felipe A
Chiang, Fu-Tien
Califf, Robert M
McMurray, John J
author_facet Preiss, David
Thomas, Laine E
Sun, Jie-Lena
Haffner, Steven M
Holman, Rury R
Standl, Eberhard
Leiter, Lawrence A
Mazzone, Theodore
Rutten, Guy E
Tognoni, Gianni
Martinez, Felipe A
Chiang, Fu-Tien
Califf, Robert M
McMurray, John J
author_sort Preiss, David
collection PubMed
description OBJECTIVES: Risk factors for cardiovascular events are well established in general populations and those with diabetes but have been sparsely studied in impaired glucose tolerance (IGT). We sought to identify predictors of (1) a composite cardiovascular outcome (cardiovascular death, non-fatal myocardial infarction and non-fatal stroke) and (2) cardiovascular death, among patients with IGT. DESIGN: We studied participants enrolled in the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. Predictors of cardiovascular events were identified in observational analyses. SETTING: Clinical trial participants in 40 countries. PARTICIPANTS: 9306 participants with biochemically confirmed IGT at high risk of cardiovascular events participated in NAVIGATOR. PRIMARY AND SECONDARY OUTCOME MEASURES: Cox proportional hazard regression models were constructed using variables (demographic data, medical history, clinical features, biochemical results and ECG findings) recorded at baseline to identify variables associated with and predictive of cardiovascular events. RESULTS: Over 6.4 years, 639 (6.9%) participants experienced a cardiovascular event, and 244 (2.6%) cardiovascular death. While predictors of both outcomes included established risk factors such as existing cardiovascular disease, male gender, older age, current smoking status and higher low-density lipoprotein cholesterol, other variables such as reduced estimated glomerular filtration rate, previous thromboembolic disease, atrial fibrillation, higher urinary albumin/creatinine ratio and chronic obstructive pulmonary disease were also important predictors. Glycaemic measures were not predictive of cardiovascular events. c-Statistics for predicting cardiovascular events and cardiovascular death were 0.74 and 0.82, respectively. This compares with c-statistics for cardiovascular events and cardiovascular death of 0.65 and 0.71, respectively, using the classical Framingham risk factors of age, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, treatment for hypertension and smoking status. CONCLUSIONS: The most powerful independent predictors of cardiovascular events in IGT included both established risk factors and other variables excluding measures of glycaemia, allowing effective identification of high-risk individuals.
format Online
Article
Text
id pubmed-3533049
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-35330492013-01-04 Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial Preiss, David Thomas, Laine E Sun, Jie-Lena Haffner, Steven M Holman, Rury R Standl, Eberhard Leiter, Lawrence A Mazzone, Theodore Rutten, Guy E Tognoni, Gianni Martinez, Felipe A Chiang, Fu-Tien Califf, Robert M McMurray, John J BMJ Open Cardiovascular Medicine OBJECTIVES: Risk factors for cardiovascular events are well established in general populations and those with diabetes but have been sparsely studied in impaired glucose tolerance (IGT). We sought to identify predictors of (1) a composite cardiovascular outcome (cardiovascular death, non-fatal myocardial infarction and non-fatal stroke) and (2) cardiovascular death, among patients with IGT. DESIGN: We studied participants enrolled in the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. Predictors of cardiovascular events were identified in observational analyses. SETTING: Clinical trial participants in 40 countries. PARTICIPANTS: 9306 participants with biochemically confirmed IGT at high risk of cardiovascular events participated in NAVIGATOR. PRIMARY AND SECONDARY OUTCOME MEASURES: Cox proportional hazard regression models were constructed using variables (demographic data, medical history, clinical features, biochemical results and ECG findings) recorded at baseline to identify variables associated with and predictive of cardiovascular events. RESULTS: Over 6.4 years, 639 (6.9%) participants experienced a cardiovascular event, and 244 (2.6%) cardiovascular death. While predictors of both outcomes included established risk factors such as existing cardiovascular disease, male gender, older age, current smoking status and higher low-density lipoprotein cholesterol, other variables such as reduced estimated glomerular filtration rate, previous thromboembolic disease, atrial fibrillation, higher urinary albumin/creatinine ratio and chronic obstructive pulmonary disease were also important predictors. Glycaemic measures were not predictive of cardiovascular events. c-Statistics for predicting cardiovascular events and cardiovascular death were 0.74 and 0.82, respectively. This compares with c-statistics for cardiovascular events and cardiovascular death of 0.65 and 0.71, respectively, using the classical Framingham risk factors of age, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, treatment for hypertension and smoking status. CONCLUSIONS: The most powerful independent predictors of cardiovascular events in IGT included both established risk factors and other variables excluding measures of glycaemia, allowing effective identification of high-risk individuals. BMJ Publishing Group 2012-12-01 /pmc/articles/PMC3533049/ /pubmed/23204139 http://dx.doi.org/10.1136/bmjopen-2012-001925 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
spellingShingle Cardiovascular Medicine
Preiss, David
Thomas, Laine E
Sun, Jie-Lena
Haffner, Steven M
Holman, Rury R
Standl, Eberhard
Leiter, Lawrence A
Mazzone, Theodore
Rutten, Guy E
Tognoni, Gianni
Martinez, Felipe A
Chiang, Fu-Tien
Califf, Robert M
McMurray, John J
Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
title Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
title_full Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
title_fullStr Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
title_full_unstemmed Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
title_short Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
title_sort predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the nateglinide and valsartan in impaired glucose tolerance outcomes research (navigator) trial
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533049/
https://www.ncbi.nlm.nih.gov/pubmed/23204139
http://dx.doi.org/10.1136/bmjopen-2012-001925
work_keys_str_mv AT preissdavid predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial
AT thomaslainee predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial
AT sunjielena predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial
AT haffnerstevenm predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial
AT holmanruryr predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial
AT standleberhard predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial
AT leiterlawrencea predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial
AT mazzonetheodore predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial
AT ruttenguye predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial
AT tognonigianni predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial
AT martinezfelipea predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial
AT chiangfutien predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial
AT califfrobertm predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial
AT mcmurrayjohnj predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial